WO2024014972A3 - Recombinant proteins, recombinant dna sequences, vectors, eukaryotic and prokaryotic expression systems and their use - Google Patents

Recombinant proteins, recombinant dna sequences, vectors, eukaryotic and prokaryotic expression systems and their use Download PDF

Info

Publication number
WO2024014972A3
WO2024014972A3 PCT/PL2023/050057 PL2023050057W WO2024014972A3 WO 2024014972 A3 WO2024014972 A3 WO 2024014972A3 PL 2023050057 W PL2023050057 W PL 2023050057W WO 2024014972 A3 WO2024014972 A3 WO 2024014972A3
Authority
WO
WIPO (PCT)
Prior art keywords
domains
domain
dna sequences
recombinant
elastin
Prior art date
Application number
PCT/PL2023/050057
Other languages
French (fr)
Other versions
WO2024014972A2 (en
Inventor
Michal Wszola
Agnieszka ROMANIK-CHRUSCIELEWSKA
Violetta Cecuda-Adamczewska
Marta Klak
Natalia Lukasiewicz
Iwona Sokolowska
Sylwester DOMANSKI
Katarzyna FLORYS-JANKOWSKA
Agnieszka ZAKRZEWSKA
Original Assignee
Fundacja Badan I Rozwoju Nauki
Polbionica Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacja Badan I Rozwoju Nauki, Polbionica Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Fundacja Badan I Rozwoju Nauki
Publication of WO2024014972A2 publication Critical patent/WO2024014972A2/en
Publication of WO2024014972A3 publication Critical patent/WO2024014972A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The subject of the invention is a recombinant hybrid protein RElSmR composed sequentially of 3 resilin domains, 1 K+ domain, 1 MMP domain, 3 elastin domains, 1 K+ domain, 4 elastin domains, 1 K+ domain, 4 elastin domains, 1 K+ domain, 3 elastin domains, 1 MMP domain, 7 RGD domains. The subject of the invention also includes a recombinant hybrid protein EJ17zipR, composed sequentially of 1 ZIP domain, 56 elastin domains, 9 silk fibroin domains, 7 RGD domains, 56 elastin domains, 10 silk fibroin domains, 7 RGD domains. The subject of the invention also includes recombinant DNA sequences encoding recombinant hybrid proteins of the invention, vectors comprising said recombinant DNA sequences of the invention, and eukaryotic or prokaryotic expression systems transformed with said recombinant DNA sequences of the invention. Finally, the subject of the invention includes uses of the recombinant hybrid proteins of the invention, and the use of the recombinant DNA sequences, vectors and eukaryotic or prokaryotic expression systems of the invention.
PCT/PL2023/050057 2022-07-12 2023-07-12 Recombinant proteins, recombinant dna sequences, vectors, eukaryotic and prokaryotic expression systems and their use WO2024014972A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22461579 2022-07-12
EP22461579.9 2022-07-12

Publications (2)

Publication Number Publication Date
WO2024014972A2 WO2024014972A2 (en) 2024-01-18
WO2024014972A3 true WO2024014972A3 (en) 2024-06-20

Family

ID=88093787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2023/050057 WO2024014972A2 (en) 2022-07-12 2023-07-12 Recombinant proteins, recombinant dna sequences, vectors, eukaryotic and prokaryotic expression systems and their use

Country Status (1)

Country Link
WO (1) WO2024014972A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220047706A1 (en) * 2018-10-17 2022-02-17 Universidad De Valladolid Composition based on recombinant biopolymers and uses of same as bio-ink
US11365225B2 (en) * 2015-11-19 2022-06-21 President And Fellows Of Harvard College Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365225B2 (en) * 2015-11-19 2022-06-21 President And Fellows Of Harvard College Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
US20220047706A1 (en) * 2018-10-17 2022-02-17 Universidad De Valladolid Composition based on recombinant biopolymers and uses of same as bio-ink

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALESSANDRA GIROTTI ET AL: "Recombinant Technology in the Development of Materials and Systems for Soft-Tissue Repair", ADVANCED HEALTHCARE MATERIALS, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 4, no. 16, 14 July 2015 (2015-07-14), pages 2423 - 2455, XP072464780, ISSN: 2192-2640, DOI: 10.1002/ADHM.201500152 *
QIAN ZHI-GANG ET AL: "Synthetic biology for protein-based materials", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 65, 31 May 2020 (2020-05-31), pages 197 - 204, XP086318318, ISSN: 0958-1669, [retrieved on 20200531], DOI: 10.1016/J.COPBIO.2020.04.004 *
SERGIO ACOSTA ET AL: "Elastin-Like Recombinamers: Deconstructing and Recapitulating the Functionality of Extracellular Matrix Proteins Using Recombinant Protein Polymers", ADVANCED FUNCTIONAL MATERIALS, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 30, no. 44, 12 March 2020 (2020-03-12), pages n/a, XP072408728, ISSN: 1616-301X, DOI: 10.1002/ADFM.201909050 *
SUN FEI ET AL: "Synthesis of bioactive protein hydrogels by genetically encoded SpyTag-SpyCatcher chemistry", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 31, 21 July 2014 (2014-07-21), pages 11269 - 11274, XP093097994, ISSN: 0027-8424, DOI: 10.1073/pnas.1401291111 *

Also Published As

Publication number Publication date
WO2024014972A2 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
WO2020018935A3 (en) De novo design of protein switches
DE69940215D1 (en) TRANSLOCATION VECTORS DERIVED FROM THE ANTENNAPEDIA HOMEODOMAIN HELIX 3
CY1113218T1 (en) HYBRID AND BILATERAL EXPERIENCE OF NACTERIUM PROTEINS
ATE329033T1 (en) HYBRID TOXINS
AU2666197A (en) Hybrid interferon compositions and methods of use
ATE238421T1 (en) INTERLEUKIN-3 (IL-3) POLYPEPTIDES WITH MULTIPLE MUTATIONS
BR9913698A (en) Enterotoxin signaling peptide ii from e. modified coli and a microorganism expressing a peptide fusion protein and a heterologous protein
Berisio et al. Polyproline and triple helix motifs in host-pathogen recognition
ATE270335T1 (en) RECOMBINANT DNA ENCODING A SIGNAL PEPTIDE, A SELECTIVELY INTERACTING POLYPEPTIDE AND A MEMBRANE ANCHOR SEQUENCE
WO2024014972A3 (en) Recombinant proteins, recombinant dna sequences, vectors, eukaryotic and prokaryotic expression systems and their use
EA202190240A1 (en) RECOMBINANT PROTEIN OPTIONS
HUP0003762A2 (en) Adipocyte-specific protein homologs
WO2020108629A8 (en) Polypeptide rdp1 and purification method and use therefor
ATE435870T1 (en) PEPTIDE INHIBITORS OF TOXINS DERIVED FROM LL-37
ES2123556T3 (en) BRADIQUININE TYPE PEPTIDES.
WO2020092769A3 (en) Silk nucleotides and proteins and methods of use
EP3666893A8 (en) D type amino acid dehydrogenase
WO2022271814A3 (en) Short apoc-ii mimetic peptides and methods of use
ATE514716T1 (en) FRAGMENTS OF TOXIN-RELATED ANTIBODIES, WITH ANTIMICROBIAL AND ANTIVIRAL ACTIVITY
MX2021011407A (en) Recombinant ccn domain proteins and fusion proteins.
DE60023933D1 (en) Hybrid-toxine von bacillus thuringiensis
ATE256747T1 (en) GLYCOSYLTRANSFERASE EXPRESSION IN ASPERGILLUS
MX2020013569A (en) Novel protein with anti-inflammatory properties.
DE69832299D1 (en) UNIQUE POLYPEPTIDES INCLUDE TROPONIN I AND TROPONIN C
MX2023000373A (en) Stabilized corona virus spike protein fusion proteins.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23772620

Country of ref document: EP

Kind code of ref document: A2